Scientists discovered that certain bacteria can trigger their own cell death as a defense mechanism against viruses, utilizing components of the bacterial immune system. This phenomenon could be exploited to develop novel antimicrobial treatments and fight drug-resistant infections.
A study published in Science Advances reveals that telomere phages, previously thought to be a rarity, are highly prevalent in Klebsiella bacteria. The discovery improves understanding of viral mechanisms and has implications for bacterial management strategies.
Scientists have discovered a novel immune signaling pathway in bacteria that turns viral infection machinery against the virus, potentially informing future biotech tools and phage therapy. This discovery reveals an ancient defense strategy that could help fight superbugs.
A new study by Virginia Tech researchers suggests that bacteriophages, or virus-like particles, may increase the sensitivity of gut bacteria to antibiotics. The team created a mouse model that allows them to control phage populations and found evidence that phages can exacerbate antibiotic damage.
Scientists at Scripps Research have imaged the structure of a phage that targets Mycobacteria, revealing a unique genome translocation mechanism and insights into the dynamic process of infection. The study provides new hope for developing effective phage therapies for antibiotic-resistant tuberculosis.
Researchers at Pitt have produced the most detailed image of a bacteriophage, revealing its structural makeup and enabling the design of phages to target specific bacterial strains. The high-definition images reveal intricate interactions between proteins in the tail tip, which binds to bacteria cells.
The 8th World Congress on Targeting Phage Therapy 2025 will bring together global phage community to address clinical, regulatory, and industrial challenges. The event will feature cutting-edge research, real-world clinical insights, and applications of bacteriophage therapy across medicine, oncology, agriculture, and industry.
A new approach to treating refractory biliary tract infections was demonstrated using personalized phage therapy. Despite initial clearance of the dominant pathogen, resistant strains emerged due to genetic mutations, highlighting the challenges posed by bacterial heterogeneity and biofilm formation.
Researchers have discovered a protective cloaking mechanism in jumbo phages that shield their genetic material from the host's immune system. This innovation could lead to new therapies for antibiotic-resistant infections.
Scientists at Johns Hopkins Medicine discovered how bacteria protect themselves from certain phage invaders by seizing genetic material from weakened, dormant phages and forming a biological 'memory' that their offspring inherit. This process allows the bacteria to recognize and fight off similar viruses in the future.
Professor Robert T. Schooley will present a talk at the 8th World Congress on Targeting Phage Therapy, exploring phage therapy advancements and necessary steps for widespread adoption. The congress will gather experts to discuss latest advances, challenges, and clinical applications of bacteriophage therapy.
A new drug screening method developed by Tampere University has found biologically active molecules that target specific tissues, potentially solving delivery issues in cancer and brain diseases. The method uses phage display and microdialysis to identify peptides with tissue-homing and penetration capabilities.
Researchers analyzed phage-bacteria communities in children's stool samples to understand their role in type 1 diabetes development. They found dynamic changes in phage and bacterial populations, suggesting an 'arms race' between the two, but no clear link to disease risk.
Researchers have discovered a new mechanism by which bacteria defend against CRISPR-Cas systems, and how phages counter these defenses. This discovery holds potential to enhance the safety and precision of CRISPR-based technologies.
Researchers at UCSF have discovered how a unique type of virus called a jumbo phage protects itself inside bacteria. The shield works via a set of secret handshakes that allow only useful proteins to pass through, giving the phage an advantage over regular phages when fighting infections.
A new genomic toolkit called Sphae has been developed to quickly assess the suitability of phage therapy for treating antibiotic-resistant bacterial strains. The platform can analyze vast datasets in under 10 minutes, prioritizing safety and flagging genes associated with toxins or undesirable traits.
New research reveals that certain antibiotics can suppress the evolution of resistance to phages in E. coli bacteria by targeting a subset of LPS mutants. By modulating these mutants, antibiotics like chloramphenicol and gentamicin reduce phage resistance.
Researchers at Indiana University found that bacteria secrete molecules, like coelechelin, which weaken competitors' immune systems and increase their vulnerability to phage infection. This discovery highlights the potential of phage-chemical combinations in treating antibiotic-resistant infections.
A new method captures RNA from diverse microbes, revealing distinct adaptive states in Prevotella and Roseburia genera. The study identifies novel host-phage transcriptional activity associations, providing insights into the complex relationships within the human gut microbiome.
A recent study found that multiple phage species can coexist stably on a genetically uniform strain of E. coli in the human gut. The researchers discovered that each phage species prefers slower or faster growing cells, allowing them to find a separate niche and maintain stable coexistence.
Researchers developed an artificial intelligence model that selects the best phage cocktail for a given patient based on their genome. The model was tested on a new collection of E. coli strains responsible for pneumonia and showed high success rates.
The study describes the full molecular structure of the phage DEV, which infects and lysates Pseudomonas aeruginosa bacteria. The researchers discovered a genome ejection motor that pulls the DNA out of its head after infection, with conserved design principles across all Schitoviridae phages.
Researchers discovered an extremely diverse collection of viruses on toothbrushes and showerheads, including previously unknown species. These bacteriophages target bacteria, not humans, and have potential uses in treating antibiotic-resistant bacterial infections.
Researchers found that a specific crosslinking mode in the peptidoglycan cell wall inhibits certain cell wall degrading enzymes, protecting bacteria from internal and external damage. This discovery may lead to new treatments for developing antibacterial therapies.
Researchers at Gladstone Institutes have developed a streamlined way to engineer bacteriophages, viruses that naturally kill bacteria. The new technique uses retrons to edit phage genomes, allowing for the creation of numerous variants and paving the way for alternative treatments for antibiotic-resistant infections.
Researchers at Montana State University have published a study in Nature describing the discovery of the PARIS immune system, which uses tRNA to neutralize viral infections. The team used advanced microscopy techniques to visualize the system's structure and function.
Researchers discovered a timer integrated into CRISPR gene scissors that enables them to switch themselves off after a viral attack. The CalpL protein triggers a signaling cascade to help the cell survive the viral attack, but breaking down cyclic oligoadenylates regulates the immune response and returns the cell to normal conditions.
Researchers discovered that infected bacteria produce a new gene, dubbed 'Neo', which rapidly arrests cell growth and induces programmed dormancy. This mechanism protects the larger bacterial population from phage infection, highlighting the potential for other 'hidden' genes to be unearthed in different biological contexts.
Researchers used advanced techniques to study phage infection at the level of individual bacterial cells. They found that coinfecting phages impede each other's entry, perturbing the cell's electrophysiology and affecting the outcome of infection. This discovery opens a new avenue for research in bacterial electrophysiology.
Research found higher bacterial concentrations in keloid tissue, especially in deep layers, leading to increased inflammation and fibroblast production. Antibiotics and phage treatments may help reduce bacteria and improve treatment outcomes for keloids.
Researchers from Rice University discovered that viruses achieve precise timing in cell lysis by balancing the buildup and breakdown of holin proteins. This balance ensures optimal cell bursting, essential for viral replication, despite underlying randomness in biological processes.
Researchers developed a strategy to identify new antimicrobial drugs with therapeutic promise from bacterial datasets. PHAb10 and PHAb11 showed robust antibacterial activity against various bacterial species, including those resistant to traditional antibiotics.
Researchers have identified a phage-derived enzyme that targets E. faecalis biofilms, reducing the severity of acute graft-versus-host disease in patients. The enzyme exhibits narrow-spectrum activity against E. faecalis and effectively lyses biofilms without affecting other bacteria.
A team of researchers led by Professor Peter Fineran from the University of Otago discovered a novel regulatory mechanism in a protein used by phages to deploy anti-CRISPR. This finding has significant implications for understanding gene regulation and developing new antimicrobial therapies.
Researchers developed a phage-displayed heptapeptide sequence that significantly improves the specific targeting ability of antimicrobial peptides against Staphylococcus aureus. The designed peptide showed higher specific antimicrobial activity against S. aureus compared to Temporin-SHf.
Researchers discovered that phage viruses have weaponized mobile introns to sabotage competing viruses' reproduction. This finding has significant implications for understanding the evolution of genomes and developing effective phage therapy against antibiotic-resistant bacteria.
Researchers have discovered that plant bacterial pathogens can acquire and repurpose elements of phages to wipe out competing microbes, potentially providing an alternative to antibiotics. This finding suggests that phage-derived elements called tailocins could be harnessed to target specific strains of bacteria.
A new study demonstrates personalized phage therapy's effectiveness in treating antibiotic-resistant infections in animals, with a case of a cat healing from a persistent wound. The treatment combines a specific anti-Pseudomonas aeruginosa phage with ceftazidime, achieving full healing after 14 weeks.
Research reveals phages infecting SAR11 bacteria, causing massive cell death and creation of 'zombie' cells. These cells, lacking ribosomes, are thought to be recycled for new phage DNA production, highlighting the importance of microbial interactions in the ocean.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
Researchers discovered a new acquired defense strategy in M. smegmatis that activates anti-phage immunity through IS transposition and silencing of the lsr2 gene island. This mechanism is distinct from the CRISPR-Cas system and involves regulation of lipid metabolism.
Scientists identify crucial protein PicA in jumbo phages that selectively transport proteins to replicate inside bacteria. This discovery sheds light on the complex biological makeup and mechanisms within these mysterious viruses.
Researchers have identified a novel pathway of interaction between the intestinal microbial ecosystem and the tumor immune microenvironment. They discovered that certain bacteria, such as C. scindens, produce secondary bile acids that suppress the effector function of CD8+ T cells, promoting colorectal cancer growth.
Researchers are developing CRISPR-Cas gene editing technology to modify and attack AMR bacteria, offering new tools to battle the increasing rates of antimicrobial resistance. By targeting specific genes and using phage-based delivery systems, scientists aim to develop safer therapies.
Researchers identified a complex of two proteins called Gabija that enhances the blockage of phage replication in bacteria. The study found that one protein alone can disable a phage's DNA, but the complex formed with its partner protein is more effective at preventing phage takeover.
Therapeutic phages can detect epithelial cells of the human respiratory tract, eliciting proinflammatory responses. Specific phage properties and airway microenvironment influence these responses.
Phage researchers at Texas A&M AgriLife Research elucidate precise mechanisms by which phages disable bacteria. The study reveals how a specific phage called PP7 infects Pseudomonas aeruginosa, leading to the pilus's detachment and reduced bacterial capacity for infection.
Researchers at ADA Forsyth Institute discovered a new phage resistance mechanism in the oral microbiome, where ultrasmall bacterial parasites, called Saccharibacteria or TM7, help their host bacteria resist lytic phages. This dynamic ecosystem promotes coexistence between antagonistic organisms.
Researchers discovered that tiny RNA molecules play a decisive role in the complex interaction of attack and defence strategies when bacteria are infected with bacteriophages. The study found that these RNA molecules regulate phage genes as well as host genes, effectively explaining the destruction of bacterial cells.
Researchers at Butantan Institute used phage display to screen 12,000 proteins from Schistosoma mansoni, identifying key parasite peptides targeted by macaque antibodies. This approach has potential for developing candidate vaccines against the disease.
Researchers propose a panoramic view of virology development in different historical periods, revealing evolutionary characteristics, motivations, and external forces. The study fills a gap in the history of virology by exploring milestones, technological achievements, and relations among elements.
A new study published in Microbiology Spectrum shows that an enzymatic cocktail can effectively kill a variety of mycobacterial species, including those causing tuberculosis. The research delivers the enzymes inside host macrophages where mycobacteria grow, increasing efficacy and reducing toxicities associated with current treatments.
Researchers deciphered a novel process helping viruses choose to be nasty or friendly to their host bacteria. Phages use the bacterial immune system to make decisions, activating violent mode when necessary.
Researchers discovered T1-spanin's exceptional capability to penetrate bacterial defenses and effectively kill nearly 120 strains. A novel phage-based technology delivers T1-spanin genes into target bacteria, providing a potential solution for tackling drug-resistant pathogens.
Scientists discovered that bacteria form partnerships between different defence systems to create a formidable force against phage viruses. This discovery could lead to new strategies for combating antimicrobial resistance and developing phage therapy as an alternative to antibiotics.
A new study describes phage therapy as a game-changing solution to combat multi-drug resistant Pseudomonas aeruginosa infections. Researchers found that sequential administration of phages and antibiotics can clear infection and re-sensitize bacteria to antibiotics.
Researchers use bacteriophages to target and kill drug-resistant bacteria, with a patient experiencing complete resolution of infection after combination therapy. However, immune response may lead to recurrence, highlighting need for further clinical trials.
A study published in Nature Communications reports the discovery of a wound-homing molecule called CAR peptide, which accelerates tissue repair by activating natural healing pathways. The treatment shows promise for treating various injuries, including muscle ruptures and bone fractures, without forming less functional scar tissue.
Northwestern University researchers successfully engineered a virus to destroy itself from the inside out, killing a deadly bacterium. The study represents a critical step towards creating new therapies to treat antibiotic-resistant infections.
Researchers at ETH Zurich have identified a virus called Paride that can infect and destroy dormant bacteria, including Pseudomonas aeruginosa. The study found that the combination of Paride and an antibiotic called meropenem was effective in killing bacteria in both laboratory cultures and mice with chronic infections.